March 2, 2021—Seegene announced it has submitted its Allplex SARS-CoV-2/FluA/FluB/RSV Assay to the FDA for emergency use authorization.
The assay is a real-time RT-PCR assay that can simultaneously detect and differentiate eight target genes including flu A, flu B, RSV A/B and three different target genes of COVID-19—S, RdRP, and N genes. The assay also includes dual targets for internal control in the same reaction tube.
“Demand for accurate and available COVID-19 testing remains high across the United States,” Jong-Yoon Chun, PhD, CEO of Seegene, said in a press statement. “This multiplex assay will provide clinicians with the ability to differentiate diagnosis between the common flu and COVID-19. It is also incredibly efficient for labs because they will only need to run a single test versus four different tests. We’re committed to bringing innovative solutions to the market and doing our part in the fight against this pandemic.”
The test is available in Europe and elsewhere around the world.